RVL Pharmaceuticals
John Parks is a seasoned sales management professional with extensive experience in the pharmaceutical and medical device industries. Currently serving as the District Sales Manager for RVL Pharmaceuticals, Inc. since February 2021, John has previously held key leadership roles, including Vice President of Commercial Operations at Dentsply Sirona, where responsibilities included overseeing a workforce of over 280 employees across multiple divisions. John’s tenure at Alcon spanned 16 years, during which leadership was demonstrated as Market Development Director and Regional Sales Manager, achieving significant business growth and team performance enhancements. An alumnus of Mississippi State University, John holds a Bachelor's degree in Computer Science, Mathematics, and Spanish.
This person is not in any offices
RVL Pharmaceuticals
RVL Pharmaceuticals plc is a specialty pharmaceutical company focused on the commercialization and development of products that target markets with underserved patient populations in the ocular and medical aesthetics therapeutic areas. The Company is currently commercializing UPNEEQ® (oxymetazoline hydrocholoride ophthalmic solution), 0.1%, for the treatment of acquired blepharoptosis, or low-lying eyelid, in adults. UPNEEQ is the first non-surgical treatment option approved by the FDA for acquired blepharoptosis.